Facebook
Twitter
Telegram
Report an ErrorVallon Pharmaceuticals Balance Sheet 2011-2024 | VLON
Annual Balance Sheet Vallon Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -48 K | -3.48 M | -613 K | - | - | - | - | - | - | - | ||
Long Term Debt |
- | 14 K | - | 14 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
14 K | 57 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 184 K | 254 K | - | - | - | - | - | - | - | - |
Total Current Liabilities |
2.7 M | 1.99 M | 2.44 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.7 M | 2.01 M | 2.52 M | 2.41 M | 1.06 M | 486 K | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-31.5 M | -18.5 M | -21.9 M | -12.6 M | -7.78 M | -4.31 M | - | - | - | - | - | - | - |
Total Assets |
2.96 M | 383 K | 8.34 M | 955 K | 4.28 M | 639 K | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
1.81 M | 9 K | 3.7 M | 109 K | - | - | - | - | - | - | - | - | - |
Book Value |
259 K | -1.62 M | 5.82 M | -1.45 M | 3.21 M | 153 K | - | - | - | - | - | - | - |
Total Shareholders Equity |
259 K | -1.62 M | 5.82 M | -1.45 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Vallon Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 14 K | - | - | - | 72 K | - | - | 146 K | 170 K | - | - | 170 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.18 M | 1.6 M | 2.07 M | 2.01 M | 2.11 M | - | 2.58 M | 2.52 M | 1.41 M | 1.79 M | 2.57 M | 2.41 M | 2.41 M | 2.41 M | 2.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-29.5 M | -27.4 M | -31.3 M | -18.5 M | -27.3 M | - | -24.5 M | -21.9 M | -18.8 M | -17.5 M | -15.2 M | -12.6 M | -12.6 M | -12.6 M | -12.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
4.4 M | 5.64 M | 2.1 M | 383 K | 5.57 M | - | 5.94 M | 8.34 M | 10.1 M | 11.6 M | 14.6 M | 955 K | 955 K | 955 K | 955 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
3.49 M | 4.8 M | 1.66 M | 9 K | 104 K | 9 K | 2.54 M | 3.7 M | 5.88 M | 10.5 M | 13 M | 109 K | 109 K | 109 K | 109 K | 3.82 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
2.23 M | 4.04 M | 31 K | -1.62 M | 3.46 M | - | 3.36 M | 5.82 M | 8.73 M | 9.85 M | 12 M | -1.45 M | -1.45 M | -1.45 M | -1.45 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
2.23 M | 4.04 M | -3.23 M | -1.62 M | -5.71 M | -5.44 M | -5.15 M | 5.82 M | 8.73 M | 9.85 M | 12 M | -1.45 M | -1.45 M | -1.45 M | -1.45 M | 3.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency